8 terminated. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
| Phase 1 | 1 | Terminated 1 |
Follow Low Back Pain: new trials by email Literature Review of Low Back Pain trials Research Report on Low Back Pain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Metformin on Low Back Pain Metformin, Placebo - Low Back Pain | Phase 2 | Terminated | Gwendolyn Sowa | 23 | 2020-01-07 | 2025-02-21 |
| Safety and Efficacy of SX600 Administered by Lumbosacral Transforaminal Epidural Injection for Radicular Pain SX600, Placebo - Lumbar Radiculopathy | Phase 1 / Phase 2 | Terminated | SpineThera Australia PTY LTD | 56 | 2019-11-04 | 2024-01-10 |
| D-cycloserine for the Treatment of Chronic, Refractory Low Back Pain D-cycloserine, Placebo - Low Back Pain, Pain | Phase 2 | Terminated | Northwestern University | 203 | 2018-03-30 | 2026-05-04 |
| Genetic Variants Associated With Low Back Pain and Their Response to Treatment With Duloxetine or Propranolol Duloxetine, Propranolol, Genotype for SNPs associated to Serotonin and COMT - Low Back Pain | Phase 2 | Terminated | Mark Ware | 10 | 2017-09-01 | 2018-08-28 |
| Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain Placebo, AbobotulinumtoxinA Treatment - Lower Back Pain | Phase 2 | Terminated | Yale University | 43 | 2012-12-01 | 2016-07-20 |
| A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain JNJ-42160443 3 mg, JNJ-42160443 1 mg, JNJ-42160443 6 mg/3mg - Low Back Pain, Low Back Pain, Recurrent | Phase 2 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 389 | 2009-09-01 | 2016-06-06 |
| Long Term Safety Study of Tanezumab in Chronic Low Back Pain Tanezumab 20 mg, Tanezumab 10 mg - Low Back Pain | Phase 2 | Terminated | Pfizer | 849 | 2009-08-20 | 2021-04-21 |
| Percutaneous Dynamic Stabilization (PDS) System Versus Fusion for Treating Degenerative Disc Disease PDS System, Fusion - Lumbar Degenerative Disc Disease | Phase 2 | Terminated | Interventional Spine, Inc. | 20 | 2009-03-01 | 2013-02-21 |
Chronic Pain (2) · Pain (2) · Back Pain (1) · Intervertebral Disc Degeneration (1) · Radiculopathy (1) · Sciatica (1)
Neurologic Manifestations (8) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (8) · Back Pain (7) · Pain (6) · Bone Diseases (1) · Mononeuropathies (1) · Musculoskeletal Diseases (1) · Nervous System Diseases (1) · Neuralgia (1) · Neuromuscular Diseases (1) · Peripheral Nervous System Diseases (1) · Sciatic Neuropathy (1) · Spinal Diseases (1)
Cycloserine (1) · Duloxetine Hydrochloride (1) · Genotype (1) · Metformin (1) · Propranolol (1) · abobotulinumtoxinA (1) · fulranumab (1) · tanezumab (1)
Gwendolyn Sowa (1) · Interventional Spine, Inc. (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Mark Ware (1) · Northwestern University (1) · Pfizer (1) · SpineThera Australia PTY LTD (1) · Yale University (1)
United States (6) · Canada (2) · Australia (1) · Belgium (1) · Netherlands (1)
Bahman Jabbari, MD (1) · Gwendolyn Sowa, MD, PhD (1) · Mark Ware, MBBS MRCP (1) · Thomas J. Schnitzer, MD, PhD (1) · Willem Volschenk (1)
PMID 24937440, PMID 26554876, PMID 27101815, PMID 35612403
2009 (1)